Laurus Labs Ltd.’s fourth-quarter revenue rose to Rs 234 crore, beating analysts’ estimates.
The online revenue of the Hyderabad-based pharma and biotech firm elevated 200% year-on-year within the quarter ended Mar 2025, in line with an trade submitting on Thursday. That compares with the Rs 189 crore consensus estimate of analysts tracked by Bloomberg.
Laurus Labs This fall FY25 Highlights (Consolidated, YoY)
-
Income up 19.5% to Rs 1,720 crore versus Rs 1,440 crore (Bloomberg estimate: Rs 1,645 crore).
-
Ebitda up 74% to Rs 421 crore versus Rs 242 crore (Estimate: Rs 414 crore).
-
Ebitda margin expanded to 24.4% versus 16.8% (Estimate: 25.2%).
-
Web revenue up at Rs 234 crore versus Rs 76 crore (Estimate: Rs 189 crore)
-
Different revenue at Rs 58.6 crore versus Rs 18.5 crore
Shares of Laurus Labs had been buying and selling 0.84% decrease at Rs 645.25 apiece as in comparison with 0.34% fall within the benchmark Nifty.
. Learn extra on Earnings by NDTV Revenue.
